Novartis AG
- Country
- 🇨🇭Switzerland
- Ownership
- Public, Private
- Established
- 1996-01-01
- Employees
- 76K
- Market Cap
- $242.6B
- Introduction
Novartis develops and manufactures innovative drugs. The firm's key areas of drug development include oncology, rare diseases, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States comprising close to one third of total revenue.
Evaluation of Cyclosporine Microemulsion and Tacrolimus on the Rate of New Onset Diabetes Mellitus in Kidney Transplantation Recipients
- Conditions
- Kidney Transplant
- Interventions
- First Posted Date
- 2005-09-15
- Last Posted Date
- 2016-11-18
- Lead Sponsor
- Novartis
- Target Recruit Count
- 693
- Registration Number
- NCT00171496
Efficacy and Safety of Diclofenac Sodium Gel in Hand Osteoarthritis
- Conditions
- Osteoarthritis
- First Posted Date
- 2005-09-15
- Last Posted Date
- 2015-04-14
- Lead Sponsor
- Novartis
- Target Recruit Count
- 360
- Registration Number
- NCT00171665
- Locations
- 🇺🇸
Alabama Clinical Therapeutics, Birmingham, Alabama, United States
🇺🇸MedSearch, LLC, Calera, Alabama, United States
🇺🇸Montgomery Rheumatology Associates, Montgomery, Alabama, United States
A 10-12 Week Study to Evaluate the Safety and Efficacy of 320 mg Valsartan and 80 mg Simvastatin in Combination and as Monotherapies in Treating Hypertension and Hypercholesterolemia
- Conditions
- HYPERTENSIONHYPERCHOLESTEROLEMIA
- First Posted Date
- 2005-09-15
- Last Posted Date
- 2017-02-23
- Lead Sponsor
- Novartis
- Target Recruit Count
- 369
- Registration Number
- NCT00171093
- Locations
- 🇺🇸
Novartis Pharmaceuticals, E. Hanover, New Jersey, United States
Trial to Evaluate the Efficacy of Fluvastatin on Certain Markers
- Conditions
- Dyslipidemia
- First Posted Date
- 2005-09-15
- Last Posted Date
- 2017-02-23
- Lead Sponsor
- Novartis
- Target Recruit Count
- 120
- Registration Number
- NCT00171262
- Locations
- 🇪🇸
Novartis, Madrid, Spain
VALORY Study of Valsartan/Hydrochlorizide for Patients Who do Not Respond Adequately to Olmesartan Medoxomil
- Conditions
- Hypertension
- First Posted Date
- 2005-09-15
- Last Posted Date
- 2023-10-18
- Lead Sponsor
- Novartis
- Target Recruit Count
- 212
- Registration Number
- NCT00171015
- Locations
- 🇨🇭
Novartis Pharmaceuticals, Basel, Switzerland
VALERIA: Valsartan in Combination With Lisinopril in Hypertensive Patients With Microalbuminuria
- Conditions
- Hypertension
- First Posted Date
- 2005-09-15
- Last Posted Date
- 2017-05-17
- Lead Sponsor
- Novartis
- Target Recruit Count
- 134
- Registration Number
- NCT00171067
- Locations
- 🇨🇭
Novartis Pharmaceuticals, Basel, Switzerland
A Study Of Valsartan Used To Treat Hypertension For Up To 13 Months In Hypertensive Children Ages 6 - 16 Years Of Age
- Conditions
- Hypertension
- First Posted Date
- 2005-09-15
- Last Posted Date
- 2016-11-18
- Lead Sponsor
- Novartis
- Target Recruit Count
- 265
- Registration Number
- NCT00171041
- Locations
- 🇺🇸
Novartis Pharmaceuticals, E.Hanover, New Jersey, United States
Study to Compare the Effect of Valsartan vs Atenolol on Pro-thrombotic State in Hypertensive Patients.
- Conditions
- Hypertension
- First Posted Date
- 2005-09-15
- Last Posted Date
- 2017-02-23
- Lead Sponsor
- Novartis
- Target Recruit Count
- 92
- Registration Number
- NCT00171756
- Locations
- 🇨🇭
Novartis, Basel, Switzerland
Atrial Fibrillation Feasibility Certoparin Trial - AFFECT
- Conditions
- Persistent Nonvalvular Atrial Fibrillation
- First Posted Date
- 2005-09-15
- Last Posted Date
- 2017-02-23
- Lead Sponsor
- Novartis
- Target Recruit Count
- 200
- Registration Number
- NCT00171769
- Locations
- 🇺🇸
Novartis Pharmaceuticals, East Hanover, New Jersey, United States
Hypertension and Cardiovascular Risk Factors
- Conditions
- HYPERTENSION
- First Posted Date
- 2005-09-15
- Last Posted Date
- 2023-10-12
- Lead Sponsor
- Novartis
- Target Recruit Count
- 76
- Registration Number
- NCT00171782